Immunotherapy adoptive

Isolated human lymphocytes are used to investigate the role of these cells in the pathogenesis of various diseases and in the autologous adoptive immunotherapy for patients with malignant disease or viral infections [39,40], Lymphocytes may be used also as biomarkers of target-organ susceptibility or as a marker of chemical effects and in the prediction of individual drug sensitivity alternatively to human liver biopsies [41, 42]. 

The obtained results demonstrated that a PEEK-WC-H F membrane bioreactor is able to support the proliferation and functions of human peripheral lymphocytes isolated from the buffy coat of healthy individuals. Therefore, the lymphocyte HF membrane bioreactor can be used as a valuable tool to maintain viable and functional lymphocytes and as an in-vitro model for pharmacological and adoptive immunotherapy. 

Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages rationale, current status, and perspectives. J Leukocyte Biol 1998 64 419-26. 

Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986 233 1318-21. 

Marcus SL, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O, Baker H. Severe hypo-vitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells. Cancer Res 1987 47(15) 4208-12. 

Feinfeld DA, D Agati V, Dutcher JP, Werfel SB, Lynn RI, Wiernik PH. Interstitial nephritis in a patient receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells. Am J Nephrol 1991 ll(6) 489-92. 

Marty C, Schwendener RA (2004) Cytotoxic tumor targeting with scFv antibody-modified liposomes. In Ludewig B, Hoffmann MW (eds) Adoptive immunotherapy methods and protocols. Methods in Molecular Medicine, vol 109. Humana, Totowa, NJ, pp 389 01... 

IL-12 may also be potentially useful for adoptive immunotherapy, especially in immunosuppressed patients (caused by cancer or HIV infection) with decreased NK function and T-cell cytotoxicity. Under appropriate conditions, IL-12 has therapeutic efficacy for promoting defense against a variety of pathogens and for use as a vaccine adjuvant to enhance beneficial Thl over detrimental Th2 lymphocyte responses and provides new tools for the development of treatment and adjuvant strategies to potentiate beneficial or inhibit detrimental endogenous immune responses. ... 

Baron F, Beguin Y. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion 2000 40 468-476. 

Adoptive immunotherapy— Administration of immune cells for the purpose of cancer treatment. 

Yamaguchi, Y, A. Ohshita, Y. Kawabuchi, K. Ohta, K. Shimizu, K. Minami, J. Hihara, E. Miyahara, and T. Toge (2003) Adoptive immunotherapy of cancer using activated autologous lymphocytes - current status and new strategies. Hum Cell 16 183-189. 

The T-cells of many cancer patients are naturally sensitized to tumor-associated antigens or can readily be sensitized with even simple vaccination maneuvers. Adoptive immunotherapy (AIT) constitutes a coordinated effort to harvest and activate such T-cells, propagate them in culture, and adoptively transfer them back into patients as therapy. Recent modifications in culture techniques, coupled... 

Hinrichs CS et al. IL-2 and IL-21 confer opposing differentiation programs to CD8 -cells for adoptive immunotherapy. Blood 2008 111 5326-5333. 

Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer building on success. Nat Rev Immunol 2006 6 383-393. 

---